BGI Genomics Co Ltd

SHE:300676 China Diagnostics & Research
Market Cap
$2.52 Billion
CN¥18.49 Billion CNY
Market Cap Rank
#5934 Global
#841 in China
Share Price
CN¥44.21
Change (1 day)
-0.92%
52-Week Range
CN¥43.90 - CN¥59.43
All Time High
CN¥248.01
Categories
Companies in China Diagnostics & Research
About

BGI Genomics Co., Ltd. engages in the provision of genomic sequencing services and proteomic services to academic institutions, pharmaceutical companies, health care providers and other organizations in China and internationally. The company offers DNA sequencing services covering whole genome sequencing, plant/animal whole genome sequencing, exome sequencing, de novo sequencing, and metagenomic … Read more

BGI Genomics Co Ltd (300676) - Net Assets

Latest net assets as of September 2025: CN¥9.37 Billion CNY

Based on the latest financial reports, BGI Genomics Co Ltd (300676) has net assets worth CN¥9.37 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥12.30 Billion) and total liabilities (CN¥2.93 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥9.37 Billion
% of Total Assets 76.18%
Annual Growth Rate 40.98%
5-Year Change 53.87%
10-Year Change 192.53%
Growth Volatility 86.2

BGI Genomics Co Ltd - Net Assets Trend (2012–2024)

This chart illustrates how BGI Genomics Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for BGI Genomics Co Ltd (2012–2024)

The table below shows the annual net assets of BGI Genomics Co Ltd from 2012 to 2024.

Year Net Assets Change
2024-12-31 CN¥9.27 Billion -7.32%
2023-12-31 CN¥10.00 Billion -2.15%
2022-12-31 CN¥10.22 Billion +8.29%
2021-12-31 CN¥9.44 Billion +56.68%
2020-12-31 CN¥6.03 Billion +36.92%
2019-12-31 CN¥4.40 Billion +3.50%
2018-12-31 CN¥4.25 Billion -0.13%
2017-12-31 CN¥4.26 Billion +23.33%
2016-12-31 CN¥3.45 Billion +8.93%
2015-12-31 CN¥3.17 Billion +116.27%
2014-12-31 CN¥1.47 Billion +145.09%
2013-12-31 CN¥597.94 Million +297.65%
2012-12-31 CN¥150.37 Million --

Equity Component Analysis

This analysis shows how different components contribute to BGI Genomics Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 6423.7% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥3.67 Billion 40.22%
Common Stock CN¥415.82 Million 4.55%
Other Components CN¥5.05 Billion 55.23%
Total Equity CN¥9.13 Billion 100.00%

BGI Genomics Co Ltd Competitors by Market Cap

The table below lists competitors of BGI Genomics Co Ltd ranked by their market capitalization.

Company Market Cap
Motor Oil (Hellas) Corinth Refineries S.A
PINK:MOHCF
 		$1.45 Billion
Primaris Retail R.E. Invest. Tr. Units
TO:PMZ-UN
 		$1.45 Billion
Dalrymple Bay Infrastructure Ltd
AU:DBI
 		$1.46 Billion
Tianma Microelectronics Co Ltd
SHE:000050
 		$1.46 Billion
Intuitive Machines Inc.
NASDAQ:LUNR
 		$1.45 Billion
Century Communities Inc
NYSE:CCS
 		$1.45 Billion
FUYO GENERAL LEASE CO.LTD
F:FXL
 		$1.45 Billion
0LUG
LSE:0LUG
 		$1.45 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in BGI Genomics Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 9,859,237,734 to 9,134,857,139, a change of -724,380,595 (-7.3%).
  • Net loss of 902,690,856 reduced equity.
  • Dividend payments of 50,363,431 reduced retained earnings.
  • Share repurchases of 780,524,843 reduced equity.
  • Other factors increased equity by 1,009,198,535.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥-902.69 Million -9.88%
Dividends Paid CN¥50.36 Million -0.55%
Share Repurchases CN¥780.52 Million -8.54%
Other Changes CN¥1.01 Billion +11.05%
Total Change CN¥- -7.35%

Book Value vs Market Value Analysis

This analysis compares BGI Genomics Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.00x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 24.17x to 2.00x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2012-12-31 CN¥1.83 CN¥44.21 x
2013-12-31 CN¥4.89 CN¥44.21 x
2014-12-31 CN¥4.64 CN¥44.21 x
2015-12-31 CN¥9.09 CN¥44.21 x
2016-12-31 CN¥9.29 CN¥44.21 x
2017-12-31 CN¥10.94 CN¥44.21 x
2018-12-31 CN¥10.41 CN¥44.21 x
2019-12-31 CN¥10.78 CN¥44.21 x
2020-12-31 CN¥14.80 CN¥44.21 x
2021-12-31 CN¥22.64 CN¥44.21 x
2022-12-31 CN¥24.59 CN¥44.21 x
2023-12-31 CN¥23.91 CN¥44.21 x
2024-12-31 CN¥22.15 CN¥44.21 x

Capital Efficiency Dashboard

This dashboard shows how efficiently BGI Genomics Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -9.88%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -23.34%
  • • Asset Turnover: 0.31x
  • • Equity Multiplier: 1.37x
  • Recent ROE (-9.88%) is below the historical average (15.56%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2012 72.18% 10.28% 0.79x 8.86x CN¥70.41 Million
2013 33.98% 12.97% 0.70x 3.74x CN¥95.89 Million
2014 2.37% 2.48% 0.55x 1.73x CN¥-90.47 Million
2015 8.47% 19.88% 0.34x 1.26x CN¥-47.40 Million
2016 9.90% 19.44% 0.40x 1.26x CN¥-3.29 Million
2017 9.60% 19.00% 0.41x 1.23x CN¥-16.77 Million
2018 9.28% 15.24% 0.48x 1.26x CN¥-29.85 Million
2019 6.41% 9.87% 0.47x 1.37x CN¥-155.07 Million
2020 35.37% 24.89% 0.75x 1.89x CN¥1.50 Billion
2021 15.68% 21.60% 0.47x 1.53x CN¥529.70 Million
2022 7.97% 11.38% 0.49x 1.43x CN¥-205.09 Million
2023 0.94% 2.14% 0.32x 1.38x CN¥-893.02 Million
2024 -9.88% -23.34% 0.31x 1.37x CN¥-1.82 Billion

Industry Comparison

This section compares BGI Genomics Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $2,602,056,913
  • Average return on equity (ROE) among peers: 5.86%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
BGI Genomics Co Ltd (300676) CN¥9.37 Billion 72.18% 0.31x $1.45 Billion
Berry Genomics Co Ltd (000710) $108.87 Million -46.67% 1.22x $377.87 Million
Zhejiang DiAn Diagnostics Co (300244) $9.50 Billion 15.09% 1.22x $1.14 Billion
Beijing Strong Biotechnologies Inc (300406) $1.70 Billion 17.66% 0.10x $317.93 Million
Ningbo MedicalSystem Biotechnology Co Ltd (300439) $308.32 Million 33.58% 0.53x $283.14 Million
Maccura Biotechnology Co Ltd (300463) $4.54 Billion 21.06% 0.45x $576.46 Million
Guangdong Hybribio Biotech Co Ltd (300639) $4.05 Billion -16.18% 0.14x $319.65 Million
Amoy Diagnostics Co Ltd (300685) $307.91 Million 21.77% 0.15x $834.75 Million
Shanghai Labway Clinical Laboratory Co Ltd (301060) $1.82 Billion -6.01% 0.44x $226.85 Million
SMO ClinPlus Co. Ltd. (301257) $1.08 Billion 12.47% 0.26x $347.98 Million